



## What is Ramadan?

- Ramadan fasting (or *sawm*) is one of the Five Pillars of Islam, considered by believers to be the foundation of Muslim life.
- Fasting occurs in the ninth month of the Islamic calendar (*Hijra*).
- The Islamic calendar is lunar based and has only 354 days. It therefore occurs 11 days earlier each year.
- Ramadan has great religious and cultural importance for Muslims. Healthcare professionals need to understand the impact this has on people with diabetes.
- Worldwide, approximately 116 million people with diabetes fast during Ramadan<sup>1</sup>.

## What does fasting entail?

- Fasting entails abstinence from food, liquid and oral medications.
- The fasting period occurs between sunrise (*suhoor*) and sunset (*iftar*).
- Ramadan lasts for 29–30 days.
- In the UK, a fast lasts 10–21 hours, depending on the season in which Ramadan falls.
- Not everyone has to fast. An individual can be exempt if they have an illness whereby fasting is detrimental.

## Who should fast?

All healthy individuals after puberty should fast. Those for whom fasting is detrimental to their health are exempt from doing so. This includes:

- Frail and elderly people.
- Children.
- Pregnant and breastfeeding women.
- People with comorbidities.

## What are the risks of fasting?

During Ramadan, a person with diabetes who decides to fast can be at risk of:

- Hypoglycaemia.
- Hyperglycaemia.
- Dehydration and thrombosis.
- Diabetic ketoacidosis.<sup>1</sup>

## What and why

- Healthcare professionals need to be aware of cultural and religious practices that can impact on a person with diabetes.
- The decision to fast for Ramadan should be made with ample discussion between the individual and healthcare provider.
- A decision should be made after assessing the risks and benefits.
- It is advisable for healthcare providers to work closely with local religious scholars to implement key messages within their community.

**Citation:** Gilani A (2019) How to manage diabetes in Ramadan. *Diabetes & Primary Care*

## References

- <sup>1</sup>International Diabetes Federation (IDF), Diabetes and Ramadan (DAR) International Alliance (2016) *Diabetes and Ramadan: Practical Guidelines*. <https://bit.ly/2kursXj>
- <sup>2</sup>Hassanein M et al (2014) Management of Type 2 diabetes in Ramadan: Low-ratio premix insulin working group practical advice. *Indian J Endocrinol Metab* **18**: 794–99
- <sup>3</sup>Muslim Spiritual Care Provision in the NHS (2017) *Ramadan Health Fact Sheet 2017*. <https://bit.ly/2P61V5U>
- <sup>4</sup>Hassanein M et al (2017) Diabetes and Ramadan: Practical guidelines. *Diabetes Res Clin Pract* **126**: 303–16
- <sup>5</sup>Ali S et al (2016) Guidelines for managing diabetes in Ramadan. *Diabet Med* **33**: 1315–29

## To fast, or not to fast?

Risk stratification by a healthcare professional should occur to establish if it is safe to fast. Factors to consider include:

- Type of diabetes.
- Individual risk of hypoglycaemia.
- Patient medications.
- Presence of comorbidities and/or complications.
- Social and work circumstances.
- Previous experience of fasting.<sup>4</sup>

## Pre-Ramadan diabetes education

A pre-Ramadan diabetes education session is advised 1–2 months before the fasting period. The benefits of a structured diabetes education programme with a Ramadan focus include fewer hypoglycaemic episodes, weight loss and improved glycaemic control<sup>1</sup>. There are six key areas that should be covered<sup>1</sup>:

- **Risk quantification.** Individuals can be stratified into one of three risk categories identified by IDF-DAR<sup>1</sup>. These are very high risk, high risk or moderate/low risk (see table over page).
- **When to break the fast.** A fast should be broken if: blood glucose levels are <3.9 or >16.7 mmol/L; there are symptoms of hypoglycaemia; or an acute illness occurs.
- **Exercise.** Light-to-moderate exercise is advisable during Ramadan.
- **Fluids and dietary advice.** A Ramadan nutrition plan is recommended (see below).
- **Blood glucose monitoring.** It is advisable to check blood glucose levels several times a day<sup>2</sup> (see right). This does not constitute breaking the fast<sup>3</sup>.
- **Medication adjustment:** see over page

## When to check blood glucose during Ramadan fasting<sup>4</sup>

1. Pre-dawn meal (*suhoor*)
2. Morning
3. Midday
4. Mid-afternoon
5. Pre-sunset meal (*iftar*)
6. 2 hours after *iftar*
7. Any time when symptoms of hypo- or hyperglycaemia, or feeling unwell.

## Medication

- In general, the bigger dose of antidiabetes medication should be given at *iftar*.
- During Ramadan, it may be prudent to pick antidiabetes agents that have a lower risk of hypoglycaemia.
- The recommendations for dose adjustment for antidiabetes agents are shown in the table below.

### IDF-DAR<sup>1</sup> risk categories and recommendations for people with diabetes who fast during Ramadan.

Risk category and religious opinion on fasting (boxed)*	Person characteristics	Comments
<b>Category 1: very high risk</b>  <b>Religious opinion:</b> Listen to medical advice. MUST NOT fast.	One or more of the following: <ul style="list-style-type: none"> <li>• Severe hypoglycaemia within the 3 months prior to Ramadan</li> <li>• DKA within the 3 months prior to Ramadan</li> <li>• Hyperosmolar hyperglycaemia within the 3 months prior to Ramadan</li> <li>• History of recurrent hypoglycaemia</li> <li>• History of hypoglycaemia unawareness</li> <li>• Poorly controlled type 1 diabetes</li> <li>• Acute illness</li> <li>• Pregnancy in pre-existing diabetes, or GDM treated with insulin or sulfonylureas</li> <li>• Chronic dialysis or CKD stages 4 and 5</li> <li>• Advanced macrovascular complications</li> <li>• Old age with ill health</li> </ul>	If individual insists on fasting, then they should: <ul style="list-style-type: none"> <li>• Receive structured education</li> <li>• Be followed by a qualified diabetes team and have access for advice during fasting</li> <li>• Check their blood glucose regularly (SMBG)</li> <li>• Adjust medication dose as per recommendations</li> <li>• Be prepared to break the fast in case of hypo- or hyperglycaemia</li> <li>• Be prepared to stop the fast in case of frequent hypo- or hyperglycaemia or worsening of other related medical conditions</li> </ul>
<b>Category 2: high risk</b>  <b>Religious opinion:</b> Listen to medical advice. SHOULD NOT fast.	One or more of the following: <ul style="list-style-type: none"> <li>• T2D with sustained poor glycaemic control**</li> <li>• Well-controlled T1D</li> <li>• Well-controlled T2D on MDI or mixed insulin</li> <li>• Pregnant T2D or GDM controlled by diet only or metformin</li> <li>• CKD stage 3</li> <li>• Stable macrovascular complications</li> <li>• People with comorbid conditions that present additional risk factors</li> <li>• People with diabetes performing intense physical labour</li> <li>• Treatment with drugs that may affect cognitive function</li> </ul>	
<b>Category 3: moderate/low risk</b>  <b>Religious opinion:</b> Listen to medical advice. Decision to use licence not to fast based on discretion of medical opinion and ability of the individual to tolerate fast.	Well-controlled T2D treated with one or more of the following: <ul style="list-style-type: none"> <li>• Lifestyle therapy</li> <li>• Metformin</li> <li>• Thiazolidinedione</li> <li>• Second-generation SUs</li> <li>• Incretin-based therapy</li> <li>• SGLT2 inhibitor</li> <li>• Basal insulin</li> </ul>	People who fast should: <ul style="list-style-type: none"> <li>• Receive structured education</li> <li>• Check their blood glucose regularly (SMBG)</li> <li>• Adjust medication dose as per recommendations</li> </ul>

\*In each category, people with diabetes should follow medical opinion if the advice is not to fast due to high probability of harm.

\*\*The level of glycaemic control is to be agreed upon with the individual, according to a multitude of factors.

CKD=chronic kidney disease; DKA=diabetic ketoacidosis; GDM=gestational diabetes mellitus; MDI=multiple-dose insulin; SGLT2=sodium-glucose cotransporter 2; SMBG=self-monitoring of blood glucose; SU=sulfonylurea; T1D=type 1 diabetes; T2D=type 2 diabetes.

## Non-insulin dose modifications for people with type 2 diabetes<sup>4</sup>

### Metformin

Daily dose remains unchanged.  
 Immediate release: daily – take at *iftar*;  
 twice daily – take at *iftar* and *suhoor*; three-times daily – morning dose at *suhoor*, combine afternoon and evening dose at *iftar*.  
 Prolonged release: take at *iftar*.

### Sulfonylurea (SU)

Switch to newer SU (gliclazide, glimepiride) where possible; glibenclamide should be avoided.  
 Once daily – take at *iftar*. Dose may be reduced in people with good glycaemic control.  
 Twice daily – *iftar* dose remains unchanged. *Suhoor* dose should be reduced in people with good glycaemic control<sup>5</sup>.  
 For once-daily SU combination therapy, take at *iftar* and consider reducing the dose by 50%.  
 For twice-daily SU combination therapy, omit morning dose and take normal dose at *iftar*.

### Thiazolidinediones

No dose modifications.  
 Dose can be taken with *iftar* or *suhoor*.

### Prandial glucose regulators (glinides)

Three-times daily dosing may be reduced/redistributed to two doses taken with *iftar* and *suhoor*.

### GLP-1 receptor agonists

No dose modifications.

### DPP-4 inhibitors

No dose modifications.

### SGLT2 inhibitors

No dose modifications.  
 Dose should be taken with *iftar*.  
 Extra clear fluids should be ingested during non-fasting periods.  
 Should not be used in the elderly, people with renal impairment, hypotensive people or those taking diuretics.

## Diet and lifestyle advice

Key messages<sup>1</sup> include:

- Low glycaemic index (GI), high fibre foods for slow energy release.
- Begin *iftar* with 1–2 dates to raise blood glucose levels and plenty of water to overcome dehydration.
- Avoid other sugary foods.
- Eat balanced meals: 45–50% carbohydrate, 20–30% protein and <35% fat.
- Take *suhoor* as late as possible.
- Maintain hydration with water and non-sweetened beverages overnight between *iftar* and *suhoor*.
- Eat foods that induce satiety (i.e. with protein and fibre).